Clinical and Experimental Hypertension

Yayıncı: Taylor & Francis Group LLC Philadelphia
Ülke: United States · Northern America
Tür: journal
ISSN: 10641963

15256006

Scopus 0,934 SJR

Scopus Q1 SJR Q

WoS Q1 JCR Q

WoS 6,8 JIF

Scopus 59 H-Index

Bütünleşik değerlendirme

Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.

WoS / JCR verileri 1997 ve sonrası içindir.

Scopus

Scopus · Scimago

SJR 0,934
Quartile Q1
H-Index 59
Atıf/yayın 6,15
Doküman (3y) 195
Atıf (3y) 759

Clarivate

Web of Science · JCR · 2025

JCR Q Q1
JIF 6,8
5Y JIF 2,8
JCI 1,16

WoS indeksleri

SCIE

Konu sınıflandırması

Kategoriler (SJR)

Internal Medicine Q2
Medicine (miscellaneous) Q1
Physiology Q2

Alanlar

Biochemistry, Genetics and Molecular Biology
Medicine

WoS kategorileri

Pharmacology & Pharmacy | Peripheral Vascular Diseases

Yıllık quartile karşılaştırması

Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.

WoS / JCR verileri 1997 ve sonrası içindir.

Not: JCR Q, JIF, 5Y JIF, JCI ve JCI Q sütunları 1997 öncesi için boştur — bu sitede WoS/JCR verisi 1997’den başlar.
Yıl	SJR Q	JCR Q (1997+)	SJR	JIF (1997+)	5Y JIF (1997+)	JCI (1997+)	JCI Q (1997+)	H-Index
2025	Q1	Q1	0,934	6,8	2,8	1,16	Q1	59
2024	Q2	Q2	0,729	3,5	2,2	0,83	Q2	57
2023	Q3	Q3	0,448	1,5	1,6	0,48	Q3	57
2022	Q3	Q3	0,438	2,6	2,1	0,6	Q2	57
2021	Q3	Q4	0,481	2,1	2	0,5	Q3	57
2020	Q3	Q4	0,555	1,7	1,8	0,53	Q3	57
2019	Q2	Q4	0,52	1,8	1,5	0,51	Q3	57
2018	—	Q4	—	1,5	1,3	0,45	Q3	—
2017	Q2	Q4	0,507	1,4	1,2	0,44	Q3	57
2016	Q3	Q4	0,42	1,2	1,1	—	—	57
2015	Q2	Q4	0,475	1,3	1,2	—	—	57
2014	Q2	Q4	0,411	1,2	1,2	—	—	57
2013	Q2	Q3	0,558	1,5	1,4	—	—	57
2012	Q2	Q3	0,468	1,3	1,3	—	—	57
2011	Q2	Q4	0,4	1,1	1,1	—	—	57
2010	Q2	Q4	0,332	1,1	1,1	—	—	57
2009	—	Q3	—	1,3	1,3	—	—	—
2008	—	Q4	—	1,1	1,1	—	—	—
2007	—	Q4	—	1	1,1	—	—	—
2006	—	Q3	—	1,1	—	—	—	—
2005	—	Q4	—	1	—	—	—	—
2004	—	Q4	—	1	—	—	—	—
2003	—	Q4	—	0,8	—	—	—	—
2002	—	Q3	—	0,9	—	—	—	—
2001	—	Q3	—	1,3	—	—	—	—
2000	—	Q3	—	1,3	—	—	—	—
1999	—	Q3	—	1,2	—	—	—	—
1998	—	Q3	—	1	—	—	—	—
1997	—	Q2	—	1,2	—	—	—	—

JCR kategori quartile geçmişi

Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.

WoS / JCR verileri 1997 ve sonrası içindir.

Not: Bu tablo 1997+ Clarivate kategori quartile kayıtlarını gösterir.
Yıl	Kategori	Edition	JCR Q (1997+)	JCI Q (1997+)	Sıra
2025	PERIPHERAL VASCULAR DISEASE	SCIE	Q1	Q1	12/100
2025	PHARMACOLOGY & PHARMACY	SCIE	Q1	Q1	37/356
2024	PERIPHERAL VASCULAR DISEASE	SCIE	Q2	Q2	26/98
2024	PHARMACOLOGY & PHARMACY	SCIE	Q2	Q2	107/352
2023	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	Q3	67/96
2023	PHARMACOLOGY & PHARMACY	SCIE	Q3	Q3	265/354
2022	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	Q2	43/68
2022	PHARMACOLOGY & PHARMACY	SCIE	Q3	Q3	183/278
2021	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	Q3	54/67
2021	PHARMACOLOGY & PHARMACY	SCIE	Q4	Q3	228/279
2020	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	Q3	57/65
2020	PHARMACOLOGY & PHARMACY	SCIE	Q4	Q3	235/276
2019	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	Q3	49/65
2019	PHARMACOLOGY & PHARMACY	SCIE	Q4	Q3	213/271
2018	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	Q3	55/65
2018	PHARMACOLOGY & PHARMACY	SCIE	Q4	Q3	218/267
2017	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	Q3	52/65
2017	PHARMACOLOGY & PHARMACY	SCIE	Q4	Q3	220/261
2016	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	56/63
2016	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	217/257
2015	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	54/63
2015	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	205/255
2014	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	53/60
2014	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	197/255
2013	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	50/65
2013	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	176/256
2012	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	50/68
2012	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	193/261
2011	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	56/68
2011	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	205/261
2010	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	54/68
2010	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	194/252
2009	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	45/61
2009	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	178/237
2008	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	48/56
2008	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	174/219
2007	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	43/54
2007	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	166/205
2006	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	37/52
2006	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	147/199
2005	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	42/51
2005	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	156/193
2004	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	42/51
2004	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	142/187
2003	PERIPHERAL VASCULAR DISEASE	SCIE	Q4	—	43/52
2003	PHARMACOLOGY & PHARMACY	SCIE	Q4	—	144/185
2002	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	37/52
2002	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	137/188
2001	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	30/50
2001	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	101/186
2000	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	28/45
2000	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	92/181
1999	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	25/44
1999	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	89/175
1998	PERIPHERAL VASCULAR DISEASE	SCIE	Q3	—	21/39
1998	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	95/178
1997	PERIPHERAL VASCULAR DISEASE	SCIE	Q2	—	19/38
1997	PHARMACOLOGY & PHARMACY	SCIE	Q3	—	81/157